ASPEN’S Clinical Pipeline

Our clinical development programs encompass both an autologous neuron replacement therapy in sporadic Parkinson’s disease (ANPD001) and a gene-corrected autologous neuron replacement therapy for genetic variants that increase the risk of Parkinson’s disease (ANPD002).

Our lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson’s disease.

We are also working to develop a gene-corrected autologous neuron therapy (ANPD002) that is in the research stage and targeted towards genetic variants associated with a higher risk of developing Parkinson’s disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA).

asn productPipelineTable web 02 01
  1. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson’s disease in a genomic era. Trends Genet. (2015) 31:140–9. 10.1016/j.tig.2015.01.004
  2. Sidransky, Ellen, et al. “Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.” New England Journal of Medicine 361.17 (2009): 1651-1661

Please note that we at Aspen Neuroscience do not make determinations on who would be eligible for participation in clinical trials, and we do not offer tours of our laboratory. At this time, our therapy has not yet been used in humans and clinical trials have not begun.